

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report: March 22, 2022**

Commission File Number: **001-40377**

**Valneva SE**

(Translation of registrant's name into English)

**6 rue Alain Bombard**

**44800 Saint-Herblain, France**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

---

On March 16, 2022, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit

[99.1](#) [Press release dated March 16, 2022](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Valveva SE  
(Registrant)

Date: March 22, 2022

/s/ Thomas Lingelbach  
Thomas Lingelbach  
Chief Executive Officer and President

**Valneva Announces Renewal of the Term of Office of its Management Board Members**

**Saint-Herblain (France), March 16, 2022** – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, announces today that its Supervisory Board has renewed the term of office of the Company's Management Board members for an additional three years starting at the end of the Company's June 2022 Annual General Meeting (AGM).

The current terms of Thomas Lingelbach, President & Chief Executive Officer, Franck Grimaud, "*Directeur Général*" and Chief Business Officer, Peter Bühler, Chief Financial Officer, Juan Carlos Jaramillo, Chief Medical Officer, and Frédéric Jacotot, General Counsel and Corporate Secretary are expiring upon the AGM.

**About Valneva SE**

Valneva is a specialty vaccine company focused on the development, production and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

**Valneva Investor and Media Contacts**

Laetitia Bachelot-Fontaine  
VP, Global Communications & European Investor Relations  
M +33 (0)6 4516 7099  
investors@valneva.com

Joshua Drumm, Ph.D.  
VP, Global Investor Relations  
M +001 917 815 4520  
joshua.drumm@valneva.com